(Q33367222)

26 July 2017

title

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer (English)

1 reference

26 July 2017

Takahiko Sugiura

1

1 reference

26 July 2017

Yutaka Ariyoshi

2

1 reference

26 July 2017

Shunichi Negoro

3

1 reference

26 July 2017

Shinichiro Nakamura

4

1 reference

26 July 2017

Harumichi Ikegami

5

1 reference

26 July 2017

Minoru Takada

6

1 reference

26 July 2017

Takashi Yana

7

1 reference

26 July 2017

Masahiro Fukuoka

8

1 reference

26 July 2017

publication date

1 August 2005

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

23

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

331-337

1 reference

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1441-3

Toxicological aspects of a novel 9-aminoanthracycline, SM-5887.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1441-3

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1441-3

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1441-3

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1441-3

Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative

21 January 2018

1 reference

12 December 2020

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1 reference

12 December 2020

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

1 reference

12 December 2020

[Evaluation of amrubicin with a 5 day administration schedule in a mouse model]

1 reference

12 December 2020

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

12 December 2020

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions

1 reference

12 December 2020

10.1007/S10637-005-1441-3

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1027127248

0 references

1 reference